User menu

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC)

Bibliographic reference Seront, Emmanuel ; Rottey, Sylvie ; Filleul, Bertrand ; Glorieux, Philippe ; Goeminne, Jean-Charles ; et. al. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC). In: BJU International, Vol. 118, no. 3, p. 408-415 (2016)
Permanent URL http://hdl.handle.net/2078.1/172053
  1. Jemal Ahmedin, Bray Freddie, Center Melissa M., Ferlay Jacques, Ward Elizabeth, Forman David, Global cancer statistics, 10.3322/caac.20107
  2. von der Maase Hans, Sengelov Lisa, Roberts James T., Ricci Sergio, Dogliotti Luigi, Oliver T., Moore Malcolm J., Zimmermann Annamaria, Arning Michael, Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer, 10.1200/jco.2005.07.757
  3. Albers P., Park S.- I., Niegisch G., Fechner G., Steiner U., Lehmann J., Heimbach D., Heidenreich A., Fimmers R., Siener R., , Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99], 10.1093/annonc/mdq398
  4. Bellmunt Joaquim, Théodore Christine, Demkov Tomasz, Komyakov Boris, Sengelov Lisa, Daugaard Gedske, Caty Armelle, Carles Joan, Jagiello-Gruszfeld Agnieszka, Karyakin Oleg, Delgado François-Michel, Hurteloup Patrick, Winquist Eric, Morsli Nassim, Salhi Yacine, Culine Stéphane, von der Maase Hans, Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract, 10.1200/jco.2008.20.5534
  5. Dreicer Robert, Li Hailun, Cooney Matthew M., Wilding George, Roth Bruce J., Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802) : A trial of the Eastern Cooperative Oncology Group, 10.1002/cncr.23503
  6. Galsky Matthew D., Mironov Svetlana, Iasonos Alexia, Scattergood Joseph, Boyle Mary G., Bajorin Dean F., Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma, 10.1007/s10637-006-9020-9
  7. Ko Yoo-Joung, Canil Christine M, Mukherjee Som D, Winquist Eric, Elser Christine, Eisen Andrea, Reaume M Neil, Zhang Liying, Sridhar Srikala S, Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study, 10.1016/s1470-2045(13)70162-1
  8. Lorusso V, Pollera C.F, Antimi M, Luporini G, Gridelli C, Frassineti G.L, Oliva C, Pacini M, De Lena M, A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum, 10.1016/s0959-8049(98)00030-6
  9. McCaffrey J A, Hilton S, Mazumdar M, Sadan S, Kelly W K, Scher H I, Bajorin D F, Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma., 10.1200/jco.1997.15.5.1853
  10. Papamichael D, Gallagher CJ, Oliver RTD, Johnson PW, Waxman J, Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter, 10.1038/bjc.1997.106
  11. Pronzato Paolo, Vigani Antonella, Pensa Floriana, Vanoli Maurizio, Tani Francesco, Vaira Franco, Second Line Chemotherapy with Ifosfamide as Outpatient Treatment for Advanced Bladder Cancer : , 10.1097/00000421-199710000-00018
  12. Vaughn David J., Srinivas Sandy, Stadler Walter M., Pili Roberto, Petrylak Daniel, Sternberg Cora N., Smith David C., Ringuette Sarah, de Wit Edwin, Pautret Virginie, George Claude, Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma : Results of a large phase 2 study, 10.1002/cncr.24460
  13. Witte Robert S., Manola Judith, Burch Patrick A., Kuzel Timothy, Weinshel Eric L., Loehrer, Sr. Patrick J., 10.1023/a:1006159525793
  14. Apolo, J Clin Oncol, 32 (2014)
  15. Bellmunt J., Gonzalez-Larriba J. L., Prior C., Maroto P., Carles J., Castellano D., Mellado B., Gallardo E., Perez-Gracia J. L., Aguilar G., Villanueva X., Albanell J., Calvo A., Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity, 10.1093/annonc/mdr023
  16. Daugaard Gedske, Sengeløv Lisa, Agerbaek Mads, Sternberg Cora N., Van Herpen Carla, Collette Sandra, Marreaud Sandrine, , Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer., 10.1200/jco.2013.31.6_suppl.252
  17. Dreicer Robert, Li Hailun, Stein Mark, DiPaola Robert, Eleff Michael, Roth Bruce J., Wilding George, Phase 2 trial of sorafenib in patients with advanced urothelial cancer : A Trial of the Eastern Cooperative Oncology Group, 10.1002/cncr.24467
  18. Gallagher David J., Milowsky Matthew I., Gerst Scott R., Ishill Nicole, Riches Jamie, Regazzi Ashley, Boyle Mary G., Trout Alisa, Flaherty Anne-Marie, Bajorin Dean F., Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer, 10.1200/jco.2009.25.3922
  19. Gerullis H., Eimer C., Ecke T. H., Georgas E., Freitas C., Kastenholz S., Arndt C., Heusch C., Otto T., A phase II trial of temsirolimus in second-line metastatic urothelial cancer, 10.1007/s12032-012-0216-x
  20. Hussain Maha H.A., MacVicar Gary R., Petrylak Daniel P., Dunn Rodney L., Vaishampayan Ulka, Lara Primo N., Chatta Gurkamal S., Nanus David M., Glode L. Michael, Trump Donald L., Chen Helen, Smith David C., Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial, 10.1200/jco.2006.08.0994
  21. Necchi Andrea, Mariani Luigi, Zaffaroni Nadia, Schwartz Lawrence H, Giannatempo Patrizia, Crippa Flavio, Morosi Carlo, Lanocita Rodolfo, Sava Teodoro, Ortega Cinzia, Messina Caterina, Sacco Cosimo, Pennati Marzia, Daidone Maria G, Nicolai Nicola, De Braud Filippo, Gianni Alessandro M, Salvioni Roberto, Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial, 10.1016/s1470-2045(12)70294-2
  22. Twardowski Przemyslaw, Stadler Walter M., Frankel Paul, Lara Primo N., Ruel Christopher, Chatta Gurkamal, Heath Elisabeth, Quinn David I., Gandara David R., Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial, 10.1016/j.urology.2010.04.025
  23. Wong Yu-Ning, Litwin Samuel, Vaughn David, Cohen Seth, Plimack Elizabeth R., Lee James, Song Wei, Dabrow Michael, Brody Marion, Tuttle Holly, Hudes Gary, Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma, 10.1200/jco.2012.41.9572
  24. Wülfing Christian, Machiels Jean-Pascal H., Richel Dirk J., Grimm Marc-Oliver, Treiber Uwe, De Groot Marco R., Beuzeboc Philippe, Parikh Roma, Pétavy Frank, El-Hariry Iman A., A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma, 10.1002/cncr.24337
  25. O'Reilly Kathryn E., Rojo Fredi, She Qing-Bai, Solit David, Mills Gordon B., Smith Debra, Lane Heidi, Hofmann Francesco, Hicklin Daniel J., Ludwig Dale L., Baselga Jose, Rosen Neal, mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt, 10.1158/0008-5472.can-05-2925
  26. Sun Shi-Yong, Rosenberg Laura M., Wang Xuerong, Zhou Zhongmei, Yue Ping, Fu Haian, Khuri Fadlo R., Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition, 10.1158/0008-5472.can-05-0917
  27. Weinstein John N., Akbani Rehan, Broom Bradley M., Wang Wenyi, Verhaak Roeland G. W., McConkey David, Lerner Seth, Morgan Margaret, Creighton Chad J., Smith Carolyn, Kwiatkowski David J., Cherniack Andrew D., Kim Jaegil, Sekhar Pedamallu Chandra, Noble Michael S., Al-Ahmadie Hikmat A., Reuter Victor E., Rosenberg Jonathan E., Bajorin Dean F., Bochner Bernard H., Solit David B., Koppie Theresa, Robinson Brian, Gordenin Dmitry A., Fargo David, Klimczak Leszek J., Roberts Steven A., Au Jessie, Laird Peter W., Hinoue Toshinori, Schultz Nikolaus, Ramirez Ricardo, Hansel Donna, Hoadley Katherine A., Kim William Y., Damrauer Jeffrey S., Baylin Stephen B., Mungall Andrew J., Gordon Robertson A., Chu. Andy, Kwiatkowski David J., Sougnez Carrie, Cibulskis Kristian, Lichtenstein Lee, Sivachenko Andrey, Stewart Chip, Lawrence Michael S., Getz Gad, Lander Eric, Gabriel. Stacey B., Creighton Chad J., Donehower Lawrence, Cherniack Andrew D., Kim Jaegil, Carter Scott L., Saksena Gordon, Schumacher Steven E., Sougnez Carrie, Freeman Samuel S., Jung Joonil, Sekhar Pedamallu Chandra, Bhatt Ami S., Pugh Trevor, Getz Gad, Beroukhim Rameen, Gabriel Stacey B., Meyerson Matthew, Mungall Andrew J., Gordon Robertson A., Chu Andy, Ally Adrian, Balasundaram Miruna, Butterfield Yaron S. N., Dhalla Noreen, Hirst Carrie, Holt Robert A., Jones Steven J. M., Lee Darlene, Li Haiyan I., Marra Marco A., Mayo Michael, Moore Richard A., Schein Jacqueline E., Sipahimalani Payal, Tam Angela, Thiessen Nina, Wong Tina, Wye Natasja, Bowlby Reanne, Chuah Eric, Guin Ranabir, Jones Steven J. M., Marra Marco A., Hinoue Toshinori, Shen Hui, Bootwalla Moiz S., Triche Jr Timothy, Lai Phillip H., Van Den Berg David J., Weisenberger Daniel J., Laird Peter W., Hansel Donna, Hoadley Katherine A., Balu Saianand, Bodenheimer Tom, Damrauer Alan P. Hoyle Jeffrey S., Jefferys Stuart R., Meng Shaowu, Mose Lisle E., Simons Janae V., Soloway Mathew G., Wu Junyuan, Kim William Y., Parker Joel S., Neil Hayes D., Roach Jeffrey, Buda Elizabeth, Jones Corbin D., Mieczkowski Piotr A., Tan Donghui, Veluvolu Umadevi, Waring Scot, Todd Auman J., Perou Charles M., Wilkerson Matthew D., Santoso Netty, Parfenov Michael, Ren Xiaojia, Pantazi Angeliki, Hadjipanayis Angela, Seidman Jonathan, Kucherlapati Raju, Lee Semin, Yang Lixing, Park Peter J., Baylin Stephen B., Wei Xu Andrew, Protopopov Alexei, Zhang Jianhua, Bristow Christopher, Mahadeshwar Harshad S., Seth Sahil, Song Xingzhi, Tang Jiabin, Zeng Dong, Chin Lynda, Guo Charles, Weinstein John N., Akbani Rehan, Broom Bradley M., McConkey David, Casasent Tod D., Liu Wenbin, Ju Zhenlin, Motter Thomas, Peng Bo, Ryan Michael, Wang Wenyi, Verhaak Roeland G. W., Su Xiaoping, Yang Ji-Yeon, Lorenzi Philip L., Yao Hui, Zhang Nianxiang, Zhang Jiexin, Mills Gordon B., Kim Jaegil, Noble Michael S., Cho Juok, DiCara Daniel, Frazer Scott, Gehlenborg Nils, Heiman David I., Lin Pei, Liu Yingchun, Stojanov Petar, Voet Doug, Zhang Hailei, Zou Lihua, Chin Lynda, Getz Gad, Bernard Brady, Kreisberg Dick, Reynolds Sheila, Rovira Hector, Shmulevich Ilya, Ramirez Ricardo, Schultz Nikolaus, Gao Jianjiong, Jacobsen Anders, Arman Aksoy B., Antipin Yevgeniy, Ciriello Giovanni, Dresdner Gideon, Gross Benjamin, Lee William, Reva Boris, Shen Ronglai, Sinha Rileen, Onur Sumer S., Weinhold Nils, Ladanyi Marc, Sander Chris, Benz Christopher, Carlin Daniel, Haussler David, Ng Sam, Paull Evan O., Stuart Joshua, Zhu Jing, Liu Yuexin, Zhang Wei, Taylor Barry S., Lichtenberg Tara M., Zmuda Erik, Barr Thomas, Black Aaron D., George Myra, Hanf Benjamin, Helsel Carmen, McAllister Cynthia, Ramirez Nilsa C., Tabler Teresa R., Weaver Stephanie, Wise Lisa, Bowen Jay, Gastier-Foster Julie M., Weinstein John N., Lerner Seth, Jian Weiguo, Tello Sebrina, Ittman Michael, Castro Patricia, McClenden Whitney D., Morgan Margaret, Gibbs Richard, Liu Yingchun, Saller Charles, Tarvin Katherine, DiPiero Jennifer M., Owens Jennifer, Bollag Roni, Li Qiang, Weinberger Paul, Czerwinski Christine, Huelsenbeck-Dill Lori, Iacocca Mary, Petrelli Nicholas, Rabeno Brenda, Swanson Pat, Shelton Troy, Curley Erin, Gardner Johanna, Mallery David, Penny Robert, Van Bang Nguyen, Thi Hanh Phan, Kohl Bernard, Van Le Xuan, Duc Phu Bui, Thorp Richard, Viet Tien Nguyen, Quang Vinh Le, Sandusky George, Burks Eric, Christ Kimberly, Gee Jason, Holway Antonia, Moinzadeh Alireza, Sorcini Andrea, Sullivan Travis, Al-Ahmadie Hikmat A., Bajorin Dean F., Bochner Bernard H., Garcia-Grossman Ilana R., Regazzi Ashley M., Solit David B., Rosenberg Jonathan E., Reuter Victor E., Koppie Theresa, Boice Lori, Kimryn Rathmell Wendy, Thorne Leigh, Bastacky Sheldon, Davies Benjamin, Dhir Rajiv, Gingrich Jeffrey, Hrebinko Ronald, Maranchie Jodi, Nelson Joel, Parwani Anil, Bshara Wiam, Gaudioso Carmelo, Morrison Carl, Alexopoulou Vina, Bartlett John, Engel Jay, Kodeeswaran Sugy, Antic Tatjana, O’Donnell Peter H., Smith Norm D., Steinberg Gary D., Egea Sophie, Gomez-Fernandez Carmen, Herbert Lynn, Jorda Merce, Soloway Mark, Beaver Allison, Carter Suzie, Kapur Payal, Lewis Cheryl, Lotan Yair, Robinson Brian, Hansel Donna, Guo Charles, Bondaruk Jolanta, Czerniak Bogdan, Akbani Rehan, Broom Bradley M., Liu Yuexin, Zhang Wei, Weinstein John N., Lerner Seth, Morgan Margaret, Kim Jaegil, Cherniack Andrew D., Freeman Samuel S., Sekhar Pedamallu Chandra, Noble Michael S., Kwiatkowski David J., Al-Ahmadie Hikmat A., Bajorin Dean F., Bochner Bernard H., Solit David B., Rosenberg Jonathan E., Reuter Victor E., Koppie Theresa, Robinson Brian, Skinner Eila, Ramirez Ricardo, Schultz Nikolaus, Hansel Donna, Kim William Y., Guo Charles, Bondaruk Jolanta, Aldape Kenneth, Czerniak Bogdan, Jensen Mark A., Kahn Ari B., Pihl Todd D., Pot David A., Srinivasan Deepak, Wan Yunhu, Ferguson Martin L., Claude Zenklusen Jean, Davidsen Tanja, Demchok John A., Mills Shaw Kenna R., Sheth Margi, Tarnuzzer Roy, Wang Zhining, Yang Liming, Hutter Carolyn, Ozenberger Bradley A., Sofia Heidi J., Eley Greg, Comprehensive molecular characterization of urothelial bladder carcinoma, 10.1038/nature12965
  28. Aveyard J S, Skilleter A, Habuchi T, Knowles M A, Somatic mutation of PTEN in bladder carcinoma, 10.1038/sj.bjc.6690439
  29. Knowles Margaret A., Platt Fiona M., Ross Rebecca L., Hurst Carolyn D., Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer, 10.1007/s10555-009-9198-3
  30. Meric-Bernstam F., Akcakanat A., Chen H., Do K.-A., Sangai T., Adkins F., Gonzalez-Angulo A. M., Rashid A., Crosby K., Dong M., Phan A. T., Wolff R. A., Gupta S., Mills G. B., Yao J., PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors, 10.1158/1078-0432.ccr-11-2123
  31. Neshat M. S., Mellinghoff I. K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J. J., Wu H., Sawyers C. L., Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, 10.1073/pnas.171076798
  32. Seront E., Rottey S., Sautois B., Kerger J., D'Hondt L. A., Verschaeve V., Canon J.-L., Dopchie C., Vandenbulcke J. M., Whenham N., Goeminne J. C., Clausse M., Verhoeven D., Glorieux P., Branders S., Dupont P., Schoonjans J., Feron O., Machiels J.-P., Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers, 10.1093/annonc/mds057
  33. Seront E, Pinto A, Bouzin C, Bertrand L, Machiels J-P, Feron O, PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation, 10.1038/bjc.2013.505
  34. Maira S.-M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., Garcia-Echeverria C., Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity, 10.1158/1535-7163.mct-08-0017
  35. Sangale Zaina, Prass Cynthia, Carlson Amy, Tikishvili Eliso, DeGrado Jorja, Lanchbury Jerry, Stone Steven, A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors : , 10.1097/pai.0b013e3181f1da13
  36. Bellmunt Joaquim, Choueiri Toni K., Fougeray Ronan, Schutz Fabio A.B., Salhi Yacine, Winquist Eric, Culine Stéphane, von der Maase Hans, Vaughn David J., Rosenberg Jonathan E., Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens, 10.1200/jco.2009.25.4599
  37. Bendell Johanna C., Kurkjian Carla, Infante Jeffrey R., Bauer Todd M., Burris Howard A., Greco F. Anthony, Shih Kent C., Thompson Dana S., Lane Cassie M., Finney Lindsey H., Jones Suzanne F., A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors, 10.1007/s10637-015-0218-6
  38. Moon du, Int J Oncol, 45, 1027 (2014)
  39. Gil-martin, Cancer Res, 73 (2014)